Basic Information
NORADRENALINE AGUETTANT 1MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
INFUSION, SOLUTION CONCENTRATE
Regulatory Information
SIN15593P
December 4, 2018
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XC01CA03
Company Information
Active Ingredients
Strength: 1mg/ml
Detailed Information
Contraindications
**CONTRAINDICATIONS** NORADRENALINE AGUETTANT should not be given to patients who are hypotensive from blood volume deficits except as an emergency measure to maintain coronary and cerebral artery perfusion until blood volume replacement therapy can be completed. If NORADRENALINE AGUETTANT is continuously administered to maintain blood pressure in the absence of blood volume replacement, the following may occur: severe peripheral and visceral vasoconstriction, decreased renal perfusion and urine output, poor systemic blood flow despite «normal» blood pressure, tissue hypoxia, and lactate acidosis. NORADRENALINE AGUETTANT should also not be given to patients with mesenteric or peripheral vascular thrombosis (because of the risk of increasing ischemia and extending the area of infarction) unless, in the opinion of the attending physician, the administration of NORADRENALINE AGUETTANT is necessary as a life-saving procedure. Cyclopropane and halothane anesthetics increase cardiac autonomic irritability and therefore seem to sensitize the myocardium to the action of intravenously administered epinephrine or norepinephrine. Hence, the use of NORADRENALINE AGUETTANT during cyclopropane and halothane anesthesia is generally considered contraindicated because of the risk of producing ventricular tachycardia or fibrillation. The same type of cardiac arrhythmias may result from the use of NORADRENALINE AGUETTANT in patients with profound hypoxia or hypercarbia.
Indication Information
**INDICATIONS AND USAGE** For blood pressure control in certain acute hypotensive states (e.g. myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension.